Navigation Links
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Date:2/6/2009

NNRTI that offers an improved drug resistance and pharmacokinetic profile would be valuable to HIV-treating physicians and patients. The preliminary clinical evidence of IDX899 supports this and warrants continued clinical study as part of GSK's growing drug pipeline in HIV."

The $34 million upfront payment by GSK to Idenix was split evenly between cash and the purchase of Idenix common stock at $6.87 per share. The effectiveness of these transactions is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended and other customary closing conditions.

About IDX899

IDX899 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Idenix has advanced IDX899 through a Phase II proof-of-concept study in HIV-1 infected treatment-naive patients that was completed in 2008. In the proof-of-concept study, patients (n=32) receiving once-daily oral administration of IDX899 achieved mean viral load reductions of 1.8 log(10), after seven days of treatment as tested with the Roche Amplicor(R) 1.5 assay. In this study, no treatment-related serious adverse events were reported and no patients discontinued. The most common adverse events observed were dyspepsia, headache and nausea; the rate of these events was similar between IDX899-treated patients and those receiving placebo. Additionally, no patterns in laboratory abnormalities between treatment groups were observed during the treatment period.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... 25, 2011 Reportlinker.com announces that a new ... Overview of the Western European ... http://www.reportlinker.com/p0363315/-Overview-of-the-Western-European-Peripheral-Interventional-Devices-Market.html The objective of ... of the largely stable European peripheral interventional devices ...
... 25, 2011 Aerocrine, Inc., an innovative medical technology ... airways, has selected R&J Public Relations, LLC of Bridgewater, ... will conduct strategic public relations for the Aerocrine brand; ... first and only hand-held device available to measure exhaled ...
Cached Medicine Technology:Reportlinker Adds Overview of the Western European Peripheral Interventional Devices Market 2R&J Public Relations Named Agency of Record for Aerocrine, Inc. 2
(Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket Down ... at the Concord Pavilion . When it comes to the ... Luke Bryan. The 37-year-old Georgia native is one of the biggest ... the entertainment business. Bryan is currently out on his “That’s My ... the many stops the tour will be making through the rest ...
(Date:7/11/2014)... are widely applied in turf and ornamentals. They enhance ... turf and ornamentals in absorption of water, nutrient uptake, ... appear healthy and strong as a result of using ... few years. The most dominating region in biostimulants markets ... share in 2013, and is estimated to grow at ...
Breaking Medicine News(10 mins):Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... published in the,April 2008 issue of The American Journal ... and all-cause mortality, an,unusual finding for which the researchers ... analyzed data from the Physicians,Health Study I which followed ... fact is, healthy adults can continue to enjoy eggs ...
... muscle-thickening disorder may also identify children at risk , , ... gene mutations responsible for cardiac hypertrophy (thickening of the ... cases of this rare but life-threatening condition in children, ... up in children who had no family history of ...
... study shows similar results , , WEDNESDAY, April 9 (HealthDay News) ... artery to the brain to prevent a stroke -- is ... a surgery called endarterectomy, a study shows. , But endarterectomy ... continue to be the treatment of choice for the 70 ...
... An aging population and a shortage of,healthcare ... can monitor,patients remotely, process data, and even alert ... new generation patient monitoring (PM) systems,earned an estimated ... this could more than double in five years, ...
... Launched earlier this month,as a members-only benefit, ... to its AVMA Collections to the general public,expanding ... and up-to-date,veterinary medical information., AVMA Collections was ... organized by topic/subject from the Journal of the,American ...
... Reade Holdings, Inc. today,announced that David D,Arezzo, Senior Vice ... to assume a senior management,position at a large southwest ... 17, 2008., The Company has initiated a search ... swiftly to identify another high caliber executive,to join the ...
Cached Medicine News:Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 3Health News:Gene Mutations for Rare Heart Disease Also Found in Kids 2Health News:Stenting as Good as Surgery for Stroke Prevention 2Health News:New Patient Monitoring Devices Handle More Than Just Vital Signs 2Health News:AVMA Opens Online Resource to General Public 2Health News:Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: